Trade Names:Cantil- Tablets 25 mg
Diminishes gastric acid and pepsin secretion; suppresses spontaneous contractions of the colon. It is a post-ganglionic parasympathetic inhibitor.
Oral absorption is low.
Over a 5-day period, 3% to 22% is excreted in the urine, with the majority appearing on day 1. The remainder appears in the feces and is presumed not to have been absorbed.
Adjunctive therapy in the treatment of peptic ulcer.
Glaucoma; obstructive uropathy (eg, bladder neck obstruction caused by prostatic hypertrophy); obstructive GI tract disease (eg, pyloric duodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable CV status in acute GI hemorrhage; toxic megacolon complicating ulcerative colitis; myasthenia gravis; allergic or idiosyncratic reactions to any component of the product or related compounds.
PO 25 or 50 mg 4 times daily, preferably with meals and at bedtime.
Store at controlled room temperature (59° to 86°F). Protect from excessive heat.
May antagonize the effect of mepenzolate.Amantadine, antiarrhythmic agents of class I (eg, quinidine), antihistamines, antipsychotic agents (eg, phenothiazines), benzodiazepines, MAOIs, narcotic analgesics (eg, meperidine), nitrates, nitrites, sympathomimetic agents, tricyclic antidepressants, other drugs with anticholinergic activity
These agents may increase certain actions or adverse reactions of anticholinergic drugs.Antacids
May interfere with mepenzolate absorption; avoid simultaneous administration.Antiglaucoma agents
Action may be antagonized by mepenzolate.Digoxin
Serum digoxin levels may be increased in patients taking slow-dissolving dosage forms.Drugs that alter GI motility (eg, metoclopramide)
Action may be antagonized by mepenzolate.
None well documented.
Mental confusion; dizziness; weakness; drowsiness; headache; nervousness; insomnia; psychosis (including signs and symptoms of confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, coma, euphoria, decreased anxiety, fatigue, insomnia, agitation, inappropriate affect).
Increased ocular tension; cycloplegia; blurred vision; dilated pupil.
Vomiting; nausea; constipation; loss of taste; bloated feeling; dry mouth.
Urinary retention; urinary hesitancy; suppression of lactation; impotence.
Anaphylaxis; decreased sweating.
Category B .
Safety and efficacy not established.
Use with caution in the elderly and in patients with autonomic neuropathy, hepatic or renal disease, ulcerative colitis, coronary heart disease, CHF, cardiac arrhythmia, tachycardia, hypertension, prostatic hypertrophy, or hyperthyroidism.
May be symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. Treatment of diarrhea with drug is inappropriate and possibly harmful.
Can occur in presence of high environmental temperature.
Headache, nausea, vomiting, blurred vision, dilated pupils, hot, dry skin, dizziness, dryness of the mouth, difficulty swallowing, CNS stimulation, curare-like action (neuromuscular blockade).
Copyright © 2009 Wolters Kluwer Health.